Overview

The pericellular matrix (PCM) is a specialized region of the cartilage extracellular matrix (ECM) that surrounds individual chondrocytes and plays a central role in maintaining cellular homeostasis, mechanotransduction, and cartilage integrity. While much of osteoarthritis (OA) research has focused on the bulk extracellular matrix and inflammatory pathways, recent insights suggest the PCM serves as a critical biological interface between the chondrocyte and its microenvironment. Understanding its structure, composition, and functional dynamics opens new avenues in joint disease modelling, tissue engineering, and regenerative therapies.

This white paper highlights the significance of the human chondrocyte PCM, its role in disease progression—particularly in OA—and how emerging technologies like microphysiological systems and other analytical tools can be leveraged to study and preserve this essential cartilage microdomain.

Introduction

Articular cartilage is a highly specialized connective tissue that provides smooth articulation, load distribution, and shock absorption within synovial joints. Central to its function is the chondrocyte, the sole cell type present in mature cartilage, which resides in a unique microenvironment defined by its surrounding ECM. However, this ECM is not homogeneous. It is hierarchically organized into distinct regions—interterritorial, territorial, and pericellular—with the **PCM constituting the innermost layer** that directly envelops each chondrocyte.

The PCM, though structurally diminutive, plays an outsized role in determining cell behaviour, signal transduction, and matrix maintenance. Often likened to a “cellular niche” or “nanomechanical sensor,” the PCM is composed of specialized matrix molecules including type VI collagen, perlecan, and fibronectin. These components create a distinct biomechanical and biochemical interface that governs how chondrocytes perceive and respond to their external environment.

Traditionally, cartilage research has focused on bulk tissue mechanics or inflammatory pathways affecting the broader ECM, often overlooking the localized but critical contributions of the PCM. Yet recent evidence suggests that PCM integrity is essential for cartilage homeostasis, and **its disruption may be one of the earliest pathological events in joint diseases such as OA**.

The degradation of the PCM in OA alters how chondrocytes experience mechanical forces, enhances their sensitivity to inflammatory mediators, and accelerates catabolic processes. Understanding how the PCM mediates these processes provides a new lens through which joint degeneration and regeneration can be studied. Furthermore, insights into PCM biology can improve tissue engineering, regenerative medicine, and the development of more physiologically relevant in vitro models.

Advancements in technologies such as organ-on-chip platforms, atomic force microscopy, and high resolution imaging now make it possible to investigate the PCM with unprecedented precision. These tools enable dynamic, high-resolution, and longitudinal studies of chondrocyte-matrix interactions within a controlled microenvironment, laying the foundation for novel therapeutic strategies that target the PCM directly.



Pericellular matrix (PCM)

Category	Key PCM Proteins
Structural	Collagen VI, IX, II (partial)
Basement membrane	Perlecan, laminin, nidogen
Proteoglycans	Aggrecan, biglycan, decorin, versican
GAG/adhesion	Hyaluronan, link protein, CD44
Cell–matrix interface	Integrins, syndecans, annexins
Regulatory/signalling	SPARC, fibronectin, thrombospondins, TIMP-3

Functional Significance of the PCM

The PCM serves as a specialized biochemical and mechanical interface between the chondrocyte and the broader extracellular matrix ECM. Despite occupying a narrow zone around each cell, the PCM is functionally distinct and indispensable for cartilage homeostasis. Its highly organized structure and unique molecular composition enable it to fulfill a wide range of biological functions that are essential for cartilage integrity, signal regulation, and mechanotransduction.

1. Mechanical Buffering and Force Transmission

One of the primary functions of the PCM is to modulate how mechanical loads from joint activity are transmitted to the chondrocyte. The PCM's composition—rich in type VI collagen, perlecan, biglycan, and other matrix proteins—endows it with specific viscoelastic properties that allow it to absorb, dissipate, and filter mechanical forces. This buffering effect protects chondrocytes from excessive mechanical stress that could otherwise trigger pro-inflammatory or apoptotic responses.

As joint loading occurs, the PCM helps distribute mechanical signals in a finely tuned manner that maintains mechanosensitive signalling pathways. Studies using atomic force microscopy and micromechanical models have demonstrated that alterations in PCM stiffness—such as those observed in aging or osteoarthritis—change how cells perceive and respond to their environment, leading to impaired mechanotransduction and catabolic gene expression.

2. Biochemical Signal Regulation and Compartmentalization

The PCM is enriched with heparan sulfate proteoglycans like perlecan, which serve as reservoirs for growth factors including transforming growth factor-beta (TGF-β), fibroblast growth factors (FGFs), and insulin-like growth factor-1 (IGF-1). By sequestering these bioactive molecules, the PCM acts as a **local biochemical signalling hub**, controlling the spatial and temporal availability of these cues to the cell.

Under specific mechanical or enzymatic stimuli, these factors can be released from the PCM, enabling a dynamic and responsive regulation of chondrocyte behavior. This compartmentalization ensures that cells are not overstimulated by systemic signals and can mount precise, localized responses to environmental changes. In pathological states such as OA, degradation of PCM components leads to dysregulated release of these signals, contributing to inflammatory cascades and matrix breakdown.

3. Matrix–Cell Communication and Integrin Signalling

The PCM facilitates direct communication between the ECM and the chondrocyte via specialized adhesion receptors, such as integrins and syndecans. These transmembrane proteins link extracellular matrix molecules to the actin cytoskeleton, mediating bidirectional mechanical and chemical signals. This interaction governs cell shape, gene expression, proliferation, and survival.

In healthy cartilage, integrin-mediated signalling in the context of a functional PCM supports anabolic pathways and matrix synthesis. However, when the PCM is disrupted—as observed in aging or inflammation—these signalling axes shift toward catabolic activity, characterized by increased expression of matrix metalloproteinases (MMPs), aggrecanases, and pro-inflammatory cytokines such as IL-1β and TNF-α.

4. Nutrient Transport and Metabolic Exchange



Due to the avascular nature of articular cartilage, chondrocytes rely entirely on diffusion for nutrient and waste exchange. The PCM regulates the molecular diffusion of nutrients, metabolites, and signalling molecules to and from the chondrocyte. Its mesh-like architecture and selective permeability ensure a controlled exchange, optimizing cellular metabolism under fluctuating mechanical loads.

Disruption of the PCM can compromise this transport efficiency, particularly under high loading conditions where interstitial flow plays a significant role. Altered transport dynamics may lead to localized hypoxia, acidosis, or nutrient deprivation—all of which are known to contribute to chondrocyte dysfunction and cartilage degeneration.

5. Homeostasis and Protection from Immune Surveillance

PCM may also provide an immunoprivileged microenvironment by physically shielding chondrocytes from circulating immune factors and by modulating immune responses via matrix-bound cytokines. This could be particularly important in the early stages of OA or post-traumatic injury, where matrix degradation products can activate immune responses. A healthy PCM may thus act as a barrier that delays or dampens the onset of inflammation.

PCM Remodelling in Osteoarthritis

OA is a multifactorial, degenerative joint disease characterized by the progressive deterioration of articular cartilage, subchondral bone remodelling, synovial inflammation, and altered joint biomechanics. Among the earliest and most crucial pathological changes observed in OA is the **remodelling and eventual degradation of the chondrocyte PCM**. As the PCM plays a vital role in regulating chondrocyte mechanotransduction, biochemical signalling, and matrix synthesis, its disruption initiates a cascade of events that compromise cartilage integrity and accelerate disease progression.

1. Early PCM Degradation as a Disease Driver

In healthy cartilage, the PCM provides mechanical cushioning and regulates molecular interactions between the chondrocyte and its extracellular environment. However, in early OA, mechanical overload, oxidative stress, and chronic low-grade inflammation contribute to enzymatic degradation of PCM components. MMPs, particularly MMP-13, and aggrecanases such as ADAMTS-4 and -5, are upregulated and begin cleaving structural PCM proteins including type VI collagen, perlecan, and hyaluronan-binding proteoglycans.

This **enzymatic breakdown** disrupts the PCM's structural integrity, exposing chondrocytes to aberrant mechanical signals and pro-inflammatory mediators. The loss of this protective niche alters cellular phenotype, leading to increased expression of catabolic genes and decreased synthesis of cartilage ECM proteins like type II collagen and aggrecan. As such, **PCM degradation is not merely a symptom of OA—it is a functional pivot point that shifts the tissue microenvironment toward catabolism and degeneration.**

2. Biomechanical Consequences of PCM Stiffening and Softening

In aging and OA, the mechanical properties of the PCM are significantly altered. Some studies report **PCM stiffening** due to glycation end-product accumulation, which makes the matrix less compliant and more brittle. This reduces its ability to buffer mechanical forces, resulting in greater strain directly transmitted to the chondrocyte cytoskeleton. In other cases, **PCM softening** is observed, particularly following proteolytic cleavage of key matrix components. This too impairs load distribution and disrupts mechanosensitive signalling pathways that regulate matrix synthesis.

Both scenarios—either excessive stiffening or softening—impair the PCM's ability to maintain mechano-homeostasis. This loss of mechanical balance can dysregulate integrin signalling and ion channel activation, contributing to abnormal calcium influx, mitochondrial dysfunction, and eventual chondrocyte apoptosis.

3. Loss of Signal Compartmentalization and Dysregulated Growth Factor Activity

A critical function of the PCM is to compartmentalize and regulate access to growth factors such as TGF-β, BMPs, and IGF-1. In OA, PCM degradation leads to **premature or excessive release** of these bioactive molecules, resulting in paradoxical effects. For instance, TGF-β released in an uncontrolled manner can shift from supporting cartilage maintenance to promoting hypertrophic differentiation and osteophyte formation, particularly in aged cartilage.

Similarly, disrupted PCM integrity leads to **reduced responsiveness to anabolic cues**. IGF-1 resistance, a well-documented feature of OA cartilage, may be partially explained by PCM damage, as this matrix domain normally supports IGF-1 receptor activation by maintaining the ligand in close proximity to the cell surface.

4. Inflammatory Amplification and Feedback Loops

The degradation products of PCM components—such as fibronectin fragments, collagen VI peptides, and hyaluronan oligomers—can act as **damage-associated molecular patterns (DAMPs)**, further activating Toll-like receptors (TLRs) and promoting inflammatory cascades. These DAMPs reinforce a **positive feedback loop**, amplifying the expression of catabolic enzymes and inflammatory cytokines (e.g., IL-1β, TNF-α), which in turn continue to degrade both the PCM and broader ECM.

Thus, PCM remodelling is not an isolated event, but a central node in OA pathogenesis that integrates mechanical, metabolic, and inflammatory inputs to regulate chondrocyte function.

5. Sex and Age-Dependent PCM Remodelling

PCM remodelling may differ by **sex and age**, potentially contributing to the higher prevalence and severity of OA in postmenopausal women. Estrogen is known to regulate the synthesis of PCM components, and its decline with age may impair PCM repair capacity, enhance matrix degradation, and reduce mechanical resilience. These sex-specific alterations underscore the importance of incorporating hormonal status into PCM research and highlight the potential of targeted regenerative strategies that restore PCM integrity in age- and sex-appropriate ways.

One of the earliest and most significant changes in OA is the degradation of the PCM. Enzymes such as matrix metalloproteinases (MMPs) and aggrecanases cleave key PCM components, weakening its mechanical integrity and altering signalling profiles. These structural disruptions amplify cellular sensitivity to stress, triggering catabolic cascades that accelerate cartilage breakdown.

Age-related stiffening of the PCM also contributes to OA pathology. As PCM mechanics deviate from their optimal biomechanical window, chondrocytes lose their ability to maintain tissue homeostasis, leading to increased inflammation, matrix degradation, and cell death.

Emerging Tools for PCM Investigation

1. Microphysiological Systems and Joint-on-a-Chip Platforms

Microfluidic organ-on-chip (OoC) technologies—particularly **joint-on-a-chip** platforms—offer powerful tools for recreating the biomechanical environment of cartilage in vitro. These systems integrate human chondrocytes within 3D biomimetic matrices, allowing for precise control over loading conditions, fluid flow, and biochemical gradients that influence PCM structure and function.

By simulating the dynamic joint microenvironment, joint-on-chip systems provide a physiologically relevant platform for studying how mechanical stress, inflammation, or pharmacologic agents affect the PCM and chondrocyte behaviour over time. Incorporating primary human cells or induced pluripotent stem cell (iPSC)-derived chondrocytes further enhances the clinical relevance of these models. When combined with **automated perfusion, real-time sensors, and live-cell imaging**, these platforms can offer unprecedented insight into the remodelling of PCM under disease-mimicking conditions.



Mechanical stimulation with pressure applied to flexible membrane, via connected air pump, and real-time visualization under the microscope during experiments

2. Advanced Biomechanical Characterization Techniques

Quantitative mechanical assessment of the PCM is essential to understand its load-bearing role and how its properties change in disease. Recent innovations in nano- and micromechanical testing include:

- **Atomic Force Microscopy (AFM):** AFM allows for nanometer-scale indentation and stiffness mapping of the PCM directly within native cartilage slices. Researchers can now compare mechanical profiles of the PCM, territorial matrix, and interterritorial matrix with high spatial resolution, even distinguishing healthy vs. osteoarthritic tissue.
- **Scanning Ion Conductance Microscopy (SICM):** A non-contact technique that measures cell surface topography and mechanical properties, offering another label-free method to assess PCM biomechanics.
- **Micropipette Aspiration and Optical Tweezers:** These techniques can measure mechanical compliance of the PCM in live cells embedded within 3D hydrogels or engineered matrices.

Such tools provide functional readouts of matrix remodelling and cellular mechanosensitivity, supporting a deeper understanding of how changes in PCM stiffness contribute to chondrocyte dysfunction.

3. High-Resolution Imaging and Labelling Technologies

The structural characterization of the PCM is rapidly advancing due to improvements in 3D imaging techniques and molecular labelling strategies:

- **Confocal and Super-Resolution Microscopy (e.g., STED, SIM):** These techniques enable visualization of PCM-specific proteins such as type VI collagen, perlecan, and fibronectin at the subcellular level. Super-resolution microscopy bridges the gap between light microscopy and electron microscopy, allowing researchers to study PCM architecture without loss of cellular context.
- **Multiphoton and Second Harmonic Generation (SHG) Microscopy:** These nonlinear optical techniques are ideal for imaging collagen-rich structures in thick cartilage tissue, enabling label-free visualization of fibrillar matrix components within the PCM.

- **Click Chemistry and Metabolic Labelling:** These methods allow real-time tracking of newly synthesized matrix proteins and glycosaminoglycans, offering insight into matrix turnover and PCM remodelling in response to external stimuli or drug treatment.

4. Molecular Profiling and Proteomics

Proteomic and transcriptomic approaches are increasingly used to characterize the molecular composition of the PCM. Techniques such as **laser capture microdissection** or **PCM-enriched microisolation** allow for spatially resolved sampling of PCM domains for downstream mass spectrometry or RNA-seq analysis. These studies have revealed the dynamic and specialized nature of the PCM, identifying unique patterns of matrix protein expression, cytokine response, and cell-ECM signalling activity.

Further, **single-cell RNA sequencing (scRNA-seq)**, when applied to chondrocytes with intact PCM, enables the discovery of novel regulatory networks influenced by PCM integrity, inflammation, or aging.

5. Automated and High-Throughput Culture Systems

Emerging automation platforms enhance PCM research by enabling long-term, reproducible culture of chondrocytes in 3D systems that preserve or mimic native PCM characteristics. Features include:

- **Automated media exchange** to maintain nutrient gradients and eliminate waste, ensuring optimal matrix homeostasis.
- **Robotic platforms** for parallel sample processing, ideal for screening disease-modifying OA drugs and assessing their impact on PCM composition and mechanical function.
- **Integrated data acquisition** from biosensors that track cell viability, metabolic activity, and mechanical stress responses in real time.

These systems improve experimental consistency and throughput, which is especially critical when studying subtle changes in PCM properties or screening candidate compounds aimed at preserving or regenerating the PCM.

The convergence of microfluidic engineering, advanced imaging, biomechanics, and molecular profiling has transformed PCM research from a historically inaccessible niche into a rapidly expanding field of study. These emerging tools are enabling researchers to explore the PCM's role in joint health with unprecedented clarity, paving the way for new diagnostics and therapeutics that address osteoarthritis at its earliest and most modifiable stage.

By leveraging these technologies in concert—particularly within automated organ-on-chip platforms—scientists can now model the complex interplay between the PCM, mechanical stress, and inflammatory mediators. This integrated approach promises to deliver not only deeper biological insight but also more predictive, human-relevant models for drug discovery and tissue regeneration.

Joint-on-a-chip technologies offer a powerful approach to model the biomechanical environment of cartilage. These platforms enable controlled application of dynamic loading conditions and real-time analysis of PCM behaviour under physiological and pathological stimuli.

Applications in Regenerative Medicine and Drug Discovery

As our understanding of the PCM evolves, so too does its potential as a novel target in regenerative medicine and pharmaceutical development. Long regarded as a passive structural element of cartilage, the PCM is now recognized as a dynamic and functional microdomain central to chondrocyte regulation, mechanotransduction, and homeostasis. Its early involvement in OA progression makes it an attractive therapeutic target, and its unique properties offer new strategies for cartilage repair, drug testing, and disease modelling.

1. Regenerative Strategies Targeting PCM Restoration

Current cartilage repair techniques—including autologous chondrocyte implantation (ACI), microfracture, and osteochondral grafting—often fail to restore a fully functional cartilage matrix, and few succeed in reconstituting a healthy PCM around newly formed chondrocytes. However, targeted regenerative approaches are emerging that aim to **restore or replicate the native PCM**, either through biomaterial scaffolds, gene therapy, or cell-based strategies.

- **Biomimetic Scaffolds:** Engineered hydrogels that incorporate PCM-mimicking molecules such as collagen VI, perlecan, and hyaluronic acid can promote the re-establishment of a native-like PCM around chondrocytes seeded within these constructs. These materials can be tuned to match the mechanical and biochemical properties of the native PCM, thereby encouraging appropriate cell-matrix interactions and tissue development.
- **Gene Editing and Molecular Enhancement:** Modifying chondrocytes or stem cells using CRISPR/Cas9 or viral vector-based approaches to **upregulate key PCM components** (e.g., COL6A1, HSPG2) holds promise for boosting endogenous PCM synthesis. This could improve the resilience of repair tissue to mechanical stress and delay disease recurrence.
- **Stem Cell-Derived Chondrocytes:** Mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) offer scalable sources of chondrocytes for regenerative therapies. Ensuring that these cells can form and maintain a robust PCM is critical to their functional integration in vivo. Research is now focusing on **preconditioning protocols** that enhance PCM development before implantation, increasing the likelihood of long-term therapeutic success.

2. PCM as a Target for Disease-Modifying Osteoarthritis Drugs (DMOADs)

Most existing OA therapies focus on symptom management—primarily pain relief—without addressing the underlying degenerative processes. Given that **PCM degradation is one of the earliest molecular events in OA**, it represents a viable target for disease-modifying therapies aimed at halting or reversing cartilage damage.

- **Enzyme Inhibitors:** Inhibiting matrix-degrading enzymes such as MMP-13 or ADAMTS-5 could preserve PCM integrity and delay downstream matrix breakdown. Some DMOAD candidates now entering clinical trials specifically monitor **PCM biomarkers** as early indicators of drug efficacy.
- **Matrix-Stabilizing Agents:** Small molecules that enhance cross-linking or inhibit oxidative modifications of PCM components (e.g., glycation inhibitors) may help

preserve the biomechanical properties of the PCM, reducing mechanical stress on chondrocytes and preventing catabolic signalling.

- **Growth Factor Delivery Systems:** Targeted delivery of IGF-1, TGF-β1, or BMP-7 to the PCM using nanoparticles or ECM-binding peptides may **restore anabolic activity** in chondrocytes and promote PCM regeneration. Such strategies are currently being tested in preclinical joint-on-chip models and explant cultures.

3. PCM-Integrated Drug Screening Platforms

Traditional drug screening for cartilage-related conditions often relies on monolayer cultures of chondrocytes, which **lose their phenotype and PCM** over time. This limits the predictive accuracy of preclinical models. Integrating PCM-preserving environments into drug testing platforms significantly enhances their physiological relevance.

- **3D Chondrocyte Cultures with Intact PCM:** Culture systems that maintain the native PCM (e.g., by embedding freshly isolated chondrocytes into 3D matrix domes or hydrogels) provide a more faithful representation of cartilage responses to pharmacological agents. These systems allow researchers to assess how drugs impact **cellular signaling through the PCM**, such as mechanosensitive ion channels and integrin pathways.
- **High-Throughput Joint-on-a-Chip Models:** These platforms incorporate mechanical loading, biochemical gradients, and real-time imaging to model OA progression in vitro. Automated versions can be scaled to screen hundreds of compounds, assessing effects on PCM integrity, chondrocyte viability, and inflammatory marker release. Such models also support **personalized medicine approaches**, using patient-derived chondrocytes to evaluate individual drug responses.



4. PCM Biomarkers for Diagnostics and Therapeutic Monitoring

The breakdown products of PCM-specific molecules—such as type VI collagen fragments or degraded perlecan—are now being explored as **early biomarkers** of cartilage degeneration. Quantifying these markers in synovial fluid, serum, or cartilage biopsies could provide a **non-**

invasive means of diagnosing early-stage OA and monitoring treatment response in clinical trials.

The identification and validation of PCM-specific biomarkers would also improve the design of adaptive clinical trials by enabling real-time patient stratification and early readouts of therapeutic efficacy.

As tools for investigating PCM behavior continue to evolve—including microphysiological systems, advanced proteomics, and high-throughput automation—new therapeutic opportunities are likely to emerge. These innovations not only promise to slow or halt disease progression but may eventually enable **full restoration of joint function** through the targeted regeneration of both cells and their supporting matrix.

Conclusion

The human chondrocyte PCM represents a critical, yet historically underappreciated, component of cartilage biology. Far from being a passive structural boundary, the PCM functions as a dynamic, biomechanically active microdomain that orchestrates key cellular processes, including mechanotransduction, biochemical signalling, and matrix turnover. Its early and progressive degradation in OA is now recognized as a pivotal driver of disease onset and progression.

Despite these insights, the PCM remains difficult to model and study using traditional in vitro systems. Two-dimensional monolayer cultures rapidly lose PCM integrity, while animal models often fail to capture human-specific molecular and mechanical cues. This persistent gap between mechanistic understanding and translational application has limited progress in developing effective disease-modifying therapies or regenerative strategies for OA.

In this context, the emergence of **joint-on-chip (JoC) platforms**—a subclass of organ-on-a-chip technologies tailored for musculoskeletal research—offers a transformative solution. These microengineered systems provide a **controlled, tunable environment that closely mimics the mechanical, structural, and biochemical complexity of human joints**, including the dynamic interactions between chondrocytes and their surrounding PCM. By incorporating patient-derived cells, 3D tissue architecture, and biomechanical loading, JoC devices enable the recreation of joint physiology in vitro with unprecedented fidelity.

Importance of Joint-on-Chip for Regenerative Medicine

For regenerative medicine, JoC platforms offer the ideal testbed for evaluating tissue-engineered constructs, stem cell therapies, and biomaterials intended to restore cartilage integrity. Critically, these systems allow researchers to assess whether implanted cells are capable of **re-establishing a functional PCM**, a prerequisite for long-term tissue integration and mechanical resilience. Furthermore, JoCs support **longitudinal monitoring**, enabling the study of how regenerative therapies evolve over time under physiologically relevant mechanical stress.

These capabilities are particularly relevant for developing **personalized regenerative strategies**. By integrating patient-specific chondrocytes or iPSC-derived cells into JoC platforms, researchers can tailor scaffold compositions, growth factor delivery regimes, and mechanical

stimulation protocols to match the needs of individual patients—ushering in a new era of precision cartilage repair.

Role in Drug Discovery and Therapeutic Assessment

In drug discovery, JoC models that preserve or mimic the native PCM allow for more predictive and translationally relevant screening of candidate compounds. These platforms support high-throughput experimentation with **mechanical stimulation, and real-time readouts** of key cellular functions such as viability, matrix production, and inflammatory response. Unlike traditional models, JoC devices can simulate early-stage OA events—such as PCM degradation—and provide **mechanistic insight** into how drugs modulate chondrocyte behaviour in this context.

Importantly, JoC platforms enable the use of **biomarkers specific to PCM remodelling**, offering new endpoints for assessing drug efficacy and disease-modifying potential. This is especially valuable for evaluating combination therapies, enzyme inhibitors, or biologics aimed at preserving the chondrocyte niche before irreversible cartilage breakdown occurs.

Final Thoughts

By integrating biologically complex systems with automation, biomechanical control, and high-content analytics, **JoC platforms represent a convergence point between engineering and medicine**. They are poised to become foundational tools in understanding joint diseases and developing interventions that reflect the intricacies of human physiology—something long out of reach for traditional in vitro or animal models.

In the study of the chondrocyte PCM, these platforms are not just helpful—they are essential. They enable the **reconstruction, manipulation, and monitoring of the PCM** in a manner that reflects in vivo conditions, providing a powerful lens through which disease mechanisms, therapeutic responses, and regenerative strategies can be explored with unprecedented precision.

As the field moves toward more human-relevant, personalized, and mechanism-informed approaches, the integration of **JoC systems into PCM research, regenerative medicine, and drug development pipelines** will be indispensable. They are the key to transforming basic matrix biology into tangible, life-changing clinical solutions for patients suffering from joint degeneration and osteoarthritis.

References

1) Early Changes in Cartilage Pericellular Matrix Micromechanobiology Portend the Onset of Post-Traumatic Osteoarthritis.
2) Osteoarthritis as a disease of the cartilage pericellular matrix
3) Chondrons and the Pericellular Matrix of Chondrocytes
4) Cracking the Pericellular Matrix Code: Exploring how MMP-2, -3, and -7 influence matrix breakdown and biomechanical properties
5) Joint-on-chip platforms: entering a new era of in vitro models for arthritis
6) The structure and function of the pericellular matrix of articular cartilage

7) Mechanical stimulation is a key component in the development of pericellular matrix around human chondrocytes
8) Emulating the chondrocyte microenvironment using multi-directional mechanical stimulation in a cartilage-on-chip
9) Assessing mechanobiology in articular chondrocytes using an Organ-on-Chip platform
10) The Extracellular Matrix of Articular Cartilage Controls the Bioavailability of Pericellular Matrix-Bound Growth Factors to Drive Tissue Homeostasis and Repair